The value of open access and a patient centric approach to oral oncolytic utilization in the treatment of Chronic Myelogenous Leukemia: A U.S. perspective-Reference-Cited by-同舟云学术

The value of open access and a patient centric approach to oral oncolytic utilization in the treatment of Chronic Myelogenous Leukemia: A U.S. perspective

Published:2017-03-04 Issue:2 Volume:17 Page:133-140
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Das Lopamudra¹,Gitlin Matthew¹,Siegartel Lisa R.²,Makenbaeva Dinara²

Affiliation:

1. BluePath Solutions, Santa Monica, CA, USA

2. Health Economics and Outcomes Research – US Medical, Bristol-Myers Squibb Company, Princeton, NJ, USA

Funder

Bristol-Myers Squibb

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2017.1305892

Reference54 articles.

1. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2013. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975_2013/

2. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

3. National Comprehensive Cancer Network. Chronic Myelogenous Leukemia - NCCN Evidence Blocks (Version 1.2016). 2016.

4. Treating Chronic Myeloid Leukemia

5. Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacoeconomic Considerations for Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia;Hematologic Malignancies;2021